Interleukin-6-174G&#x003E;C gene promoter polymorphism and prognosis in patients with cancer

Kan Zhai; Yong Yang; Zhi-Gang Gao; Jie Ding

doi:10.18632/oncotarget.17771

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer

Kan Zhai _, Yong Yang, Zhi-Gang Gao and Jie Ding

PDF | HTML | How to cite

Oncotarget. 2017; 8:44490-44497. https://doi.org/10.18632/oncotarget.17771

Metrics: PDF 1724 views | HTML 2039 views | ?

Abstract

Kan Zhai1, Yong Yang2, Zhi-Gang Gao2 and Jie Ding1

1Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

2Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

Correspondence to:

Kan Zhai, email: [email protected]

Keywords: Interleukin-6, polymorphism, cancer, prognosis, meta-analysis

Received: February 14, 2017 Accepted: April 15, 2017 Published: May 10, 2017

ABSTRACT

Interleukin-6 (IL-6) is known to be involved in the pathogenesis of cancer progression. IL-6-174G>C polymorphism has shown several results in association studies. In this study, we evaluated the association the IL-6-174G>C polymorphism and overall survival (OS) of cancer using 17 eligible studies with 4,304 patients. Our meta-analysis indicated that IL-6-174G>C polymorphism is not associated with OS when assessed using 3 genotype comparison including GG/(GC+CC), CC/(GC+GG) and CC/GG. Interestingly, compared to GG carrier, patients with IL-6-174GC genotype showed a decreased hazard of poor OS (hazard ratio = 0.81, 95% confidence interval: 0.68–0.96, P = 0.018; I² = 34.5%, Phet = 0.107). However, for GG/(GC+CC) genotype comparison, this SNP is affect patients’ OS obviously in bladder cancer, ovarian and peritoneal cancer, neuroblastoma, gastric cancer and osteosarcoma, though pooled results showing negative association because adverse and protective effect on different type of cancer balance each other. These results suggest IL-6-174G>C polymorphism might play a role in modulating OS in different type of cancer and might contribute to individual treatment in the future.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17771

Publication Alerts

Research Papers:

Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer

Abstract